2017/01 - JP Morgan HC Conference

JP Morgan Healthcare Conference Olivier Brandicourt – Chief Executive Officer

San Francisco - January 10, 2017

2

Forward Looking Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Company’s ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

3

Agenda

Reshaping the portfolio

Progress on our strategic roadmap in 2016

Focused on key product launches

Sustain innovation in R&D

Outlook

Focused on key launches: Toujeo®, Soliqua™, Praluent®, Dengvaxia®

2016: Sanofi Progressing on its Strategic Priorities

4

Vaccines JV in Europe discontinued(2); EU Generics to be carved out

5 NMEs(3) start Ph 3: isatuximab, PD-1, sotagliflozin, olipudase alfa, NeoGAA

Priority review granted for Dupixent® in Atopic Dermatitis

Streamlined GBU organization driving financial performance

Simplify

Reshape

Innovation

Launches

BI asset swap makes Sanofi a global leader in Consumer Healthcare(1)

(1) Sanofi and Boehringer Ingelheim confirm closing of business swap on January 1st, 2017 (2) Sanofi Pasteur and MSD end joint vaccines business in Europe on January 2nd, 2017 (3) NME: New Molecular Entity

Icons designed by Freepik

5

Agenda





Outlook

Sanofi Genzyme

(Specialty Care)

● Rare diseases

● Multiple Sclerosis

● Immunology

● Oncology

Shaping a Leading Portfolio of Diversified Businesses with an Attractive Long-term Growth Profile

6

(1) YTD September at constant exchange rates (CER) (2) Excluding Venezuela and Consumer Healthcare (CHC) (3) On a comparable structure basis and excluding Venezuela (4) BI sales for YTD September 2016

General Medicines &

Emerging Markets

● Leader in EM

● EU Generics (YTD Sep sales €610m) carve-out expected to take 12-24 months

Consumer Healthcare

● Allergy ● Cough & Cold ● Digestive ● Pain ● VMS

€3,684m +19.1%

Diabetes & Cardiovascular

● Leading basal insulin franchise

● PCSK9

9 Months 2016 Sales by Global Business Unit(1)

Sanofi Pasteur

(Vaccines)

● Flu vaccine ● Polio/Pertussis/Hib ● Meningitis/

Pneumonia ● Dengue

€3,225m +11.0%

€10,853m(2) -1.8%

€4,687m -3.9%

€2,496m +2.3%(3)

+ Boehringer Ingelheim(4)

€1,132m

4.4% 4.4% 4.4%

4.2%

3.5% 2.4% 1.9% 1.0%

73.8%

BI Asset Swap: A Strong Strategic Rationale for Our Ambitions in Consumer Healthcare (CHC)

7

Other

Reckitt Benckiser

Pfizer

J&J

GSK

Takeda P&G

Bayer +

(1) Nicholas Hall & Company, MAT Q3 2016 (2) Excludes BI CHC in China

● Market share of 4.4% in 2016(1,2)

● Leverage scale in a fragmented market ● Opportunity for strategic consolidation ● Expand global footprint

● Brand equity offers more sustainable revenue streams ● No patent cliff ● ‘Ever-lasting’ brands

Sanofi to Become a Top Player in the €113bn OTC Market(1)

Reinforces ambition to be a diversified global healthcare leader focused on human health

A Value Creating Transaction Based on Strong Financials

● Combined CHC global sales of around €4.9bn in 2015(1)

● Focus on a portfolio of high-value self medications

(1) Excludes Boehringer Ingelheim CHC in China; value of CHC sales in Venezuela have been reduced to nearly zero due to revision of foreign exchange rates by both companies

● Synergies in advertising and promotional activities

● Global commercial platform for OTC launches and Rx switches

● BOI margin contribution expected to be around 30% in 2018

● Expect transaction to be business EPS neutral in 2017 and accretive in subsequent years

BI Consumer Healthcare €6.7bn plus gross cash payment €4.7bn

Sanofi Animal Health €11.4bn

8

Financial implications Increased Scale in CHC Business Value creation

9

BI Transaction Increases Scale of Sanofi CHC Portfolio in Attractive Categories and Important Geographies

● Highly complementary portfolio boosts market position in priority categories

● 6 iconic brands generate 60% of BI CHC sales in 2015

● BI footprint complementary in strategically important countries(2)

● Japan (€299m), U.S. (€186m) and Germany (€162m)

(1) Nicholas Hall & Company, MAT Q3 2016 (2) BI sales in 2015

Global size in €bn(1)

33.1 #5 #3

19.6 #10 #6

16.2 #5 #1

15.4 #4 #2

3.8 #3 #2

1.0 #1 #1

+

Market Rank(1,2)

Sanofi Global Categories

/

10

Agenda





Outlook

11

®

Focus on 6 Major Launches to Drive Future Growth

12

- Capturing Share in Key Markets

(1) IMS Rapid weekly as of December 21th, 2016 (2) Market Share of the Basal insulin market in International Units for France, Germany, Spain, UK and Japan, in TRx

for the U.S.;

Toujeo® Market Share(1,2) Top EU Countries, Japan and the U.S.

● Toujeo® generated sales €411m YTD September 2016

● 6.8% TRx market share in the U.S.(1)

● Launched in 35 countries

● U.S. formulary status remains favorable

● >3/4 commercial lives covered in 2017

● Solid performance in top EU countries despite introduction of biosimilar glargine

● Strong rebound in Japan following the lifting of the 2-week prescription limitation in September 2016

0%

5%

10%

15%

20%

W0 W10 W20 W30 W40 W50 W60 W70 W80 W90

France Germany UK Spain Japan U.S.

Week since launch

13

- Important Addition to our Diabetes Franchise

● U.S. FDA approval of Soliqua™ 100/33 ● Once-daily fixed-ratio combination of Lantus® and

GLP-1 receptor agonist Adlyxin® (lixisenatide) ● Indicated for adults with type 2 diabetes

inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide

● Administered with the SoloStar® pen device

● SOLIQUA™ 100/33 U.S. product profile ● Wide dosing range (15 to 60 units of insulin)

in a single pen ● Flexible switching regimen with recommended

starting dose of 15 or 30 units

● Positive CHMP opinion on SULIQUA™ in Nov 16; EU regulatory decision anticipated in Jan 17

>50% of people with diabetes remain uncontrolled on basal insulin(1)

(1) Banegas JR, et al. Eur Heart J. 2011;32(17):2143-52, DOI: 10.1093/eurheartj/ehr080; Stark Casagrande S, et al. Diabetes Care. 2013;36(8):2271-9, DOI: 10.2337/dc12-2258; Vouri SM, et al. J Manag Care Pharm. 2011;17(4):304-12, http://www.ncbi.nlm.nih.gov/pubmed/21534641

Launched in the U.S. January 4, 2017

http://www.ncbi.nlm.nih.gov/pubmed/21534641

14

Praluent® is developed and commercialized in collaboration with Regeneron (1) Internal estimates (2) IMS Health

● Sanofi and Regeneron will appeal the District Court’s rulings in the Federal Circuit Court of Appeals, including requesting a stay of the injunction during the pendency of the appeal

● Will vigorously defend our case through the appeal process as we believe that Amgen’s asserted patent claims are invalid and the facts and controlling law support our position

● Praluent® continues to be available to patients ● More than 18,000 patients in the U.S. treated(1)

● Approximately 85% of prescriptions are dispensed at the low 75mg dose(2)

● ODYSSEY OUTCOMES trial expected to complete in late 2017 as planned ● DMC will continue to monitor study ● Focused on patients with the highest medical need

- Litigation and Product Update

Re-submission for Regulatory Review in the U.S. expected in Q1 2017

15

U.S. launch preparation activities ongoing

Sarilumab is developed in collaboration with Regeneron Pharmaceuticals, Inc. Sarilumab is an investigational agent under clinical development and its safety and efficacy has not been fully evaluated by any Regulatory Authority (1) Subject to successful FDA prelicense inspection related to dupilumab (2) Most frequently reported Treatment Emergent Adverse Events include serious infections, injection site erythema and neutropenia (3) Based on one head to head superiority study comparing sarilumab and Humira in improving signs and symptoms of RA in adults (MONARCH).

A second confirmatory study has not been conducted. Neutropenia, which was not associated with infections, was more common with sarilumab than Humira®. Not included in the initial BLA filed with FDA; Humira® (adalimumab) is an AbbVie brand

● Based on review of responses to the FDA 483 as well as proposed corrective actions, the FDA has classified the Le Trait ‘fill and finish’ facility as “acceptable”

● Expect FDA inspection of Le Trait and re-submission of sarilumab BLA in Q1 2017(1)

● IL-6 plays key roles in the local joint symptoms and systemic manifestations of rheumatoid arthritis (RA)

● Positive Phase 3 efficacy/safety data in methotrexate-inadequate responder (IR) and difficult-to-treat TNF-IR populations(2)

● Positive sarilumab monotherapy efficacy data compared to Humira® monotherapy(3)

16

First-in-Class Biologic for Adults with Moderate to Severe Atopic Dermatitis

Atopic Dermatitis (AD)

● Characterized by intense itching and recurrent eczematous lesions

● Multifactorial etiology involving immune-mediated inflammation, genetic factors, and environmental triggers

● Although it often starts in infancy, it is also highly prevalent in adults

IGA 4 IGA 1

● BSA affected: 86.5% ● EASI score: 51.5 ● Pruritus NRS: 7 ● AD duration: 48 years

● BSA affected: 2.5% ● EASI score: 3.1 ● Pruritus NRS: 1.6

BLA accepted for priority review by the FDA with PDUFA date of March 29, 2017

®

Pictures from Phase 3 clinical trial provided for illustration purposes only to show how the clinical parameters above may correlate to the clinical presentation of a patient.(1)

Dupixent® is developed in collaboration with Regeneron Pharmaceuticals, Inc. Dupixent® is an investigational agent under clinical development and its safety and efficacy has not been fully evaluated by any Regulatory Authority IGA: Investigator Global Assessment BSA: Body Surface Area EASI: Eczema Area and Severity Index NRS: Numerical Rating Scale (1) Images are taken from one patient at baseline (left) and at 16 weeks (right). Results were not representative of all patients and individual results did

vary. In phase 3 clinical trials, the percentage of patients achieving an IGA score of 0 or 1 ranged from 36%-38%. Adverse events that were higher for Dupixent® vs placebo included injection site reactions and conjunctivitis; Photo used with permission

Launch Focused on Patients with the Highest Unmet Medical Need

17

Physician Focus

Target physicians with experience

prescribing biologics (i.e. Psoriasis)

Up to 7,000 doctors

in the U.S.

Patient Focus

Intolerant to or inadequate response

to an existing therapy (e.g. Topicals,

Oral/systemic steroids, Immuno-suppressants)

Around 300,000 adult patients

in the U.S.

Dupixent® is developed in collaboration with Regeneron Pharmaceuticals, Inc. Dupixent® is an investigational agent under clinical development and its safety and efficacy has not been fully evaluated by any Regulatory Authority

®

18

A Pipeline in One Product - Clinical Studies in Multiple Indications Underway

Nasal polyposis Phase 3 started in Q4 2016

Asthma Phase 3 fully enrolled and U.S. submission

expected in Q4 2017

Atopic dermatitis (AD) Phase 3, March 29 FDA PDUFA Date Accepted for review by EMA in Dec 2016

Type 2, including Th-2 mediated diseases

DUPILUMAB

Eosinophilic esophagitis Ph 2 data exp. H2 17 Food allergy Phase 2 expected to start 2017

Additional Indications

Pediatric expansion in AD(1) and Asthma Ph 3 studies in AD (age 6-11 and 12-17) and

Asthma (age 6-11) expected to start Q1 2017

(1) FDA Breakthrough designation for adults and pediatric moderate to severe atopic dermatitis

19

- Update on Launches in Endemic Countries

(1) Bolivia, Brazil, Cambodia, Costa Rica, El Salvador, Guatemala, Indonesia, Mexico, Paraguay, Peru, the Philippines, Thailand and Singapore (2) http://www.who.int/wer/2016/wer9130.pdf?ua=1

● Dengvaxia® approved in 13 countries(1)

● License application filed in 31 endemic countries including the U.S. FDA in Dec 2016

● ~750,000 people administered to date

● Sales of €50m in first 9 months of 2016 ● Sales largely from Philippines and

Paraná state in Brazil ● Working on roll-out of immunization

program in other states of Brazil

WHO recommends vaccination in high disease burden geographies(2)

20

Agenda




Outlook


21

Expanding Pipeline in Leadership Categories: Diabetes and Rare Diseases

Sotagliflozin

● Dual SGLT1 and SGLT2 inhibitor(1)

● Limiting meal time glucose absorption and increasing renal glucose excretion

● Oral administration ● Favorable safety profile ● Positive Phase 3 data in

Type 1 diabetes announced ● Phase 3 program in Type 2

diabetes started in 2016

Olipudase alfa NeoGAA

● Rare genetic lysosomal storage disorder: Second-generation therapy for Pompe disease

● NeoGAA(3) glycan structure could potentially have efficacy, safety and convenience advantages

● First patient enrolled in pivotal Phase 3 COMET study in November 2016

● Rare genetic lysosomal storage disorder: Acid sphingomyelinase deficiency, ASMD(2)

● FDA Breakthrough Therapy designation

● Leveraging Sanofi Genzyme’s strong presence in hematology

● Pivotal Phase 2/3 trial started in July 2016

(1) SGLT2 (sodium-glucose cotransporter type 2) is a transporter responsible for most of the glucose reabsorption performed by the kidney; SGLT1 (sodium-glucose cotransporter type 1) is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney

(2) Also known as Niemann-Pick Type B (3) GAA: Genetic deficiency or dysfunction of the lysosomal enzyme acid alpha-glucosidase

22

Re-Building a Competitive Position in Oncology

MoA: Mechanism of Action (1) HDeckert, et al. Clin Cancer Res 2014;20:4574–83. (2) ICARIA-MM: A phase 3 randomized, open-label, multicenter study comparing Isatuximab (SAR650984) in Combination with Pomalidomide And Low-

Dose Dexamethasone verRsus Pomalidomide and Low-Dose Dexamethasone In patients with refractory or relapsed and refractory Multiple Myeloma

Isatuximab (anti-CD38)

● Pivotal Phase 2/3 study in cutaneous squamous cell carcinoma ongoing

● Phase 2 study in basal cell carcinoma expected to start in H1 2017

● Start of Phase 2 study in non-small cell lung cancer planned for H1 2017

PD-1 (REGN2810)

Sanofi’s Antibody Drug Conjugates (ADCs) in Phase 1 complementary to our multi-specific antibody platform and IO strategy

● Product profile potentially differentiated ● Targets unique epitope with a distinct combination MoA(1)

● Phase 3 study in relapsed/refractory multiple myeloma initiated in December(2)

● Potential indications beyond multiple myeloma being explored

23

Agenda





Outlook

Driving Financial Performance on our 2020 Roadmap

Deliver stated financial objectives

● FY2016 EPS guidance raised in October

● FY2017 guidance to be released on Feb 8th, 2017

Achieve targeted cost savings ● At least €1.5bn by 2018

● Re-investment of savings will be scaled

€3.5bn buy-back commitment by year-end 2017 ● €1.7bn shares repurchased since Q3 results

● Potential additional opportunistic SBB

Financial Targets

2016 - 2017 Accelerate growth from

priority launches Continue to build scale

in priority businesses Capture margin

improvement

2018 - 2020

24

Accelerate Growth

Health & Medicine

2017/01 - JP Morgan HC Conference